COVID-19: risk for cytokine targeting in chronic inflammatory diseases?,Nature Reviews Immunology

当前位置： X-MOL 学术 › Nat. Rev. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Nature Reviews Immunology ( IF 67.7 ) Pub Date : 2020-05-01 , DOI: 10.1038/s41577-020-0312-7
Georg Schett _{1,

2} , Michael Sticherling _{2,

3} , Markus F Neurath _{2,

4}

Affiliation

COVID-19, caused by the SARS-CoV-2 virus, has become pandemic. With sharply rising infection rates, patient groups characterized by an enhanced infection risk will be challenged by the virus. In this context, patients with chronic immune-mediated inflammatory diseases are of particular interest, as these diseases are characterized by an intrinsic immune dysfunction leading to inflammation that may enhance risk for severe infection. Immune-mediated inflammatory diseases are often treated with cytokine blocking therapy. This comment discusses whether such therapies may pose a risk — or even a benefit — in the context of the current COVID-19 pandemic.

中文翻译：

COVID-19：慢性炎症性疾病中细胞因子靶向的风险？

由 SARS-CoV-2 病毒引起的 COVID-19 已成为大流行病。随着感染率的急剧上升，以感染风险增加为特征的患者群体将受到病毒的挑战。在这种情况下，患有慢性免疫介导的炎症性疾病的患者特别受关注，因为这些疾病的特征在于导致炎症的内在免疫功能障碍，这可能会增加严重感染的风险。免疫介导的炎性疾病通常用细胞因子阻断疗法治疗。本评论讨论了在当前 COVID-19 大流行的背景下，此类疗法是否可能带来风险甚至益处。

更新日期：2020-04-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11